STOCK TITAN

NewGenIvf Group Limited Announces Closing of $2.5 Million Underwritten Offering

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

NewGenIvf Group (NIVF) closed a firm-commitment underwritten offering that raised approximately $2.5 million in gross proceeds before underwriting fees and other offering expenses.

At closing, the offering comprised 9,501,148 Class A ordinary shares at $0.035 each and pre-funded warrants at $0.03499 each to buy up to 61,927,422 shares. NewGenIvf plans to use approximately $625,000 of gross proceeds to repurchase $584,112 in Exchange Note principal. The company expects to use net proceeds and existing cash for Nodexus cytometry technology and assisted reproductive services expansion and commercialization, further prediction-market and digital-asset/AI investments, UAE real estate interests and general corporate purposes.

Loading...
Loading translation...
4 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointClosed underwritten offering raised approximately $2.5 million in gross proceeds 45× market cap
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Nodexus cytometry technology and assisted reproductive services are slated for commercialization and expansion using net proceeds and existing cash
  • Minor point. Forward-looking: it has not happened yet and may not happen.Planned Exchange Note repurchase allocates approximately $625,000 of gross proceeds to repurchase $584,112 in principal
  • Minor point. Forward-looking: it has not happened yet and may not happen.Further prediction-market and digital-asset/AI investments are among the company's planned uses of net proceeds and existing cash

Negative

  • Major pointShare dilution from 9,501,148 Class A ordinary shares at $0.035 each, with potential further dilution from $0.03499 pre-funded warrants covering up to 61,927,422 shares
  • Minor pointUnderwriting fees and other offering expenses are payable by NewGenIvf and reduce gross proceeds

News Explained

Management retains broad discretion over how the net proceeds are applied among the listed uses.

At the completed offering, NewGenIvf sold pre-funded warrants for up to 61,927,422 shares, immediately exercisable at $0.00001 each; exercise would add shares and reduce existing holders’ percentage ownership.

Key Figures

Gross proceeds: approximately $2.5 million Class A Ordinary Shares sold: 9,501,148 shares Pre-funded warrants: up to 61,927,422 shares +5 more
Gross proceeds
approximately $2.5 million
Underwritten offering; before fees and expenses
Class A Ordinary Shares sold
9,501,148 shares
Offering at closing
Pre-funded warrants
up to 61,927,422 shares
Shares purchasable under warrants at closing
Share offering price
$0.035 per share
Class A Ordinary Shares
Warrant offering price
$0.03499 per warrant
Pre-funded warrants
Warrant exercise price
$0.00001 per warrant
Pre-funded warrants
Gross proceeds allocated to note repurchase
approximately $625,000
Exchange Note repurchase
Exchange Note principal repurchased
$584,112
Exchange Note repurchase

Key Terms

firm commitment, pre-funded warrants, shelf registration statement, prospectus supplement
4 terms
firm commitment financial
"previously announced firm commitment underwritten offering"
An underwriting agreement where an investment bank guarantees to buy an entire new issue of securities from an issuer and then resell them to the public. Think of it as a store owner agreeing to buy a whole shipment upfront so the seller gets paid immediately; for investors this matters because it reduces the risk that the offering will fail, sets the initial supply and price pressure in the market, and signals underwriter confidence in selling the shares.
pre-funded warrants financial
"pre-funded warrants to purchase Class A Ordinary Shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shelf registration statement regulatory
"pursuant to an effective shelf registration statement on Form F-3"
A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.
prospectus supplement regulatory
"A final prospectus supplement and accompanying prospectus"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BANGKOK, Nov. 20, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a technology-driven, diversified growth company, today announced the closing of its previously announced firm commitment underwritten offering with gross proceeds to the Company of approximately $2.5 million, before deducting underwriting fees and other offering expenses payable by the Company.

The offering consisted of 71,428,570 Class A Ordinary Shares (or pre-funded warrants to purchase Class A Ordinary Shares in lieu thereof (the “Pre-Funded Warrants”)). At closing, the offering comprised 9,501,148 Class A Ordinary Shares and Pre-Funded Warrants to purchase up to 61,927,422 Class A Ordinary Shares. The offering price per Class A Ordinary Share was $0.035 (or $0.03499 for each Pre-Funded Warrant, which is equal to the offering price per Class A Ordinary Share sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant sold in the offering, the number of Class A Ordinary Shares in the offering will be decreased on a one-for-one basis.

Aggregate gross proceeds to the Company were approximately $2.5 million. The transaction closed on November 20, 2026. The Company expects to use the net proceeds from the offering, together with its existing cash, for commercialization and expansion of the Nodexus advanced cytometry technology and our assisted reproductive services platform, further strategic investments in prediction-market and digital-asset/AI initiatives, our real estate interests in the UAE, and other general corporate purposes. Our management will retain broad discretion to apply these net proceeds. We will also apply approximately $625,000 of the gross proceeds of this offering to repurchase $584,112 in principal amount of the Exchange Note. The Company’s Class A Ordinary Shares are listed on the Nasdaq Capital Market under the symbol “NIVF”.

Aegis Capital Corp. acted as the sole book-running manager for the offering. Han Kun Law Offices LLP acted as U.S. counsel to the Company. Kaufman & Canoles, P.C. acted as U.S. counsel to Aegis Capital Corp.

The offering was made pursuant to an effective shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.

Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About NewGenIvf Group Limited

NewGenIvf Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. The Company’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the anticipated use of proceeds from the offering, the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. For a discussion of the risks and uncertainties that could cause actual results to differ materially, see the section entitled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 and in the final prospectus supplement relating to the offering. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor Contact:
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did NewGenIvf (NIVF) raise in its underwritten offering?

NewGenIvf received approximately $2.5 million in gross proceeds before underwriting fees and other offering expenses.

When can holders exercise NewGenIvf (NIVF) pre-funded warrants, and what is the exercise price?

The pre-funded warrants are immediately exercisable at $0.00001 per warrant and may be exercised at any time until exercised in full. The exercise price is separate from the $0.03499 offering price per warrant.

Keep reading